Merck & Co., Inc (NYSE: MRK) Continues Its Expansion With Planned Acquisition of Seagen Inc

Merck & Co., Inc (NYSE: MRK) has announced that it is in discussion to purchase Seagen Inc. and may reach an agreement as earlier as this month, according to people familiar with the matter. Merck to offer $200 per share to buy Seagen One of the sources stated that a sale price of around $200 per […]

Merck (NYSE:MRK) Receives Approval for KEYTRUDA From the EMA As First-Line MSI-H/dMMR Colorectal Cancer Treatment

Merck (NYSE:MRK) has announced that the European Medicines Agency’s Committee for Medicinal Product for Human Use has adopted a positive view recommending KEYTRUDA approval. EMA’s CHMP approves KEYTRUDA as MSI-H/dMMR cancer treatment KEYTRUDA is the company’s anti-PD-1 therapy used as a monotherapy for first-line mismatch repair deficient (dMMR) or metastatic microsatellite instability-high (MSI-H) colorectal cancer […]

Merck (NYSE:MRK) Makes Investment In Seattle Genetics Inc. (NASDAQ:SGEN) For Development Of Ladiratuzumab Vedotin

Merck (NYSE:MRK) has entered a development agreement for Seattle Genetics Inc. (NASDAQ:SGEN) ladiratuzimab vedotin antibody-drug conjugate (ADC). Merck joins Gilead in investing in ADC-developer with a stake in Seattle Genetics The agreement came hours after Gilead Sciences Inc. (NYSE:GILD) announced the acquisition of Immunomedics for $21 billion. The centerpiece of Gilead’s deal is Immunomedic’s anti-Trop-2 […]